Pascal Brière – President, Biogaran, France
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Address: 15 bd Charles de Gaulle 92707 Colombes ,France
Tel: +33 (0)1 55 72 41 00
Biogaran, is an independent French laboratory focused on generic drugs and was born in 1996 at the initiative of the first independent French pharmaceutical group: Servier.
Today the group is second on the French market and produces 55% of its products within the country. The laboratory Biogaran has commissioned the Social Security savings of around € 1 billion since its inception in 1996.
The group distributes a wide variety of pharmaceutical medications through French pharmacies
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
An early bronchiolitis outbreak has put French paediatric hospital services under pressure and forced the government to react with the provision of EUR 150 million in emergency funds, but this…
French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers. Servier, which is governed…
Exor, led by Fiat brand heirs the Agnelli family, has signed a partnership agreement for an investment of EUR 833 million in the also family-owned French holding, Institut Mérieux, known…
The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies…
France is Europe’s 4th largest pharmaceutical manufacturer, having produced pharmaceuticals valued at €21.9 billion in 2019. In recent years, the French contract development and manufacturing organisation (CDMO) market has seen…
When British executive Paul Hudson joined French pharma Sanofi back in 2019, he was quick to launch a “play to win” strategy, shedding underperforming areas and doubling down on its…
See our Cookie Privacy Policy Here
